202 completed, 93 unknown, 52 recruiting, 32 terminated. 417 Phase 3, 67 Phase 2.
Follow Stomach Diseases: new trials by email Literature Review of Stomach Diseases trials Research Report on Stomach Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer | Phase 3 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 820 | 2027-06-30 | 2026-09-29 |
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer Apatinib Mesylate Tablets - Gastric Cancer, Surgery | Phase 3 | Not yet recruiting | Fujian Medical University | 118 | 2026-12-25 | 2026-01-02 |
| Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis | Phase 3 | Recruiting | Hua Huang, MD, PhD | 170 | 2026-12-01 | 2026-10-16 |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer DWP14012 40mg (Fexuprazan), Lansoprazole 30mg - Gastric Ulcer | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 384 | 2026-10-15 | 2026-07-28 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma Alternative Postoperative Treatment Regimen, Original Treatment Regimen, Postoperative Observation - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 405 | 2026-06-01 | 2026-05-22 |
| A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment BL-M05D1, Paclitaxel, Docetaxel - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Biokin (Shanghai) Biopharmaceutical Co., Ltd. | 438 | 2026-05-15 | 2026-11-02 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| Quality of Life After Billroth II or Roux-en-Y for Gastric Cancer Billroth 2 (B2), Roux-En-Y (REY) - Gastric (Cardia, Body) Cancer | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 250 | 2026-03-20 | 2026-05-20 |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 690 | 2026-03-13 | 2026-09-30 |
| Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE) Conversion Surgery, Systemic Therapy/Standard of Care - Gastric Cancer Stage IV, Peritoneal Metastasis | Phase 2 / Phase 3 | Active not recruiting | National University Hospital, Singapore | 300 | 2026-02-21 | 2026-05-14 |
| PROGAIN Trial in Gastric Cancer Surgery Protein-enriched peripheral parenteral nutrition (Winuf A+ injection), Standard peripheral parenteral nutrition (Winuf injection) - Stomach (Gastric) Cancer | Phase 3 | Recruiting | Soonchunhyang University Hospital | 110 | 2026-02-13 | 2026-05-19 |
| Holy Basil in The Treatment of Dyspepsia Holy basil extract - Dyspepsia and Other Specified Disorders of Function of Stomach | Phase 2 / Phase 3 | Recruiting | Mahidol University | 27 | 2026-02-13 | 2026-03-24 |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 Sonesitatug vedotin, Rilvegostomig, Nivolumab - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | AstraZeneca | 2130 | 2026-02-03 | 2026-10-16 |
| Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer Robotic Gastrectomy, Laparoscopic Gastrectomy - Gastric Cancer (GC) | Phase 3 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 335 | 2026-02-01 | 2026-01-12 |
| A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Disitamab Vedotin, Tislelizumab, CAPOX (oxaliplatin/capecitabine) - Gastric Carcinoma | Phase 3 | Recruiting | RemeGen Co., Ltd. | 555 | 2026-01-12 | 2026-09-22 |
| Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer Oxaliplatin plus S-1, Docetaxel plus S-1 - Gastric Cancer (GC), Adjuvant Chemotherapy | Phase 3 | Recruiting | Ruijin Hospital | 387 | 2025-12-15 | 2026-01-26 |
| Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Balstilimab, Botensilimab, Folfox Protocol - Gastric Cancer, MSI-H | Phase 3 | Recruiting | Centre Leon Berard | 132 | 2025-12-08 | 2026-06-25 |
Showing 20 of 417. Sign in to see all of them.
Stomach Neoplasms (301) · Stomach Ulcer (43) · Duodenal Ulcer (27) · Gastroparesis (20) · Esophagitis, Peptic (19) · Esophageal Neoplasms (18) · Peptic Ulcer (18) · Diabetes Mellitus (12) · Gastritis (12) · Neoplasms (12) · Adenocarcinoma (11) · Adenocarcinoma Of Esophagus (11) · Vomiting (11) · Nausea (9)
Digestive System Diseases (414) · Gastrointestinal Diseases (414) · Digestive System Neoplasms (301) · Neoplasms by Site (301) · Gastrointestinal Neoplasms (298) · Neoplasms (292) · Intestinal Diseases (91) · Duodenal Diseases (80) · Peptic Ulcer (62) · Pathological Conditions, Signs and Symptoms (52) · Esophageal Diseases (39) · Signs and Symptoms (34) · Gastroenteritis (31) · Neurologic Manifestations (27)
Oxaliplatin (68) · Capecitabine (56) · Fluorouracil (44) · Cisplatin (40) · S 1 (combination) (28) · Docetaxel (26) · Lansoprazole (26) · Leucovorin (22) · Paclitaxel (21) · Esomeprazole (18) · Irinotecan (15) · apatinib (15) · Nivolumab (14) · Trastuzumab (14) · pembrolizumab (13)
AstraZeneca (19) · Takeda (19) · Chinese University of Hong Kong (10) · Fudan University (10) · Sun Yat-sen University (10) · Hoffmann-La Roche (8) · Merck Sharp & Dohme LLC (8) · National Cancer Center, Korea (8) · POZEN (8) · Samsung Medical Center (7) · Fujian Medical University (6) · Taiho Pharmaceutical Co., Ltd. (6) · Allergan (5) · Amgen (5) · Asan Medical Center (5)
China (147) · South Korea (110) · Japan (88) · United States (78) · Germany (55) · Italy (46) · Poland (44) · Taiwan (42) · France (41) · Canada (39) · United Kingdom (38) · Spain (37) · Australia (36) · Brazil (33) · Belgium (30)
Everardus Orlemans, PhD (4) · Il Ju Choi, M.D., Ph.D. (4) · Paula Fernstrom (4) · Enders K.W. Ng, MD (3) · Mitsuru Sasako, MD (3) · Salah-Eddin Al-Batran, MD (3) · Dazhi Xu, PHD, MD (2) · Francis K Chan, MD (2)
PMID 40341124, PMID 19735233, PMID 20195905, PMID 21129076, PMID 19183157, PMID 19681809, PMID 21104822, PMID 22226517, PMID 23451835, PMID 24118079, PMID 27211503, PMID 27891632, PMID 28716815, PMID 28988197, PMID 29196436, PMID 30557792, PMID 33792646, PMID 35623069, PMID 37037952, PMID 38140879, PMID 38308771, PMID 38861294, PMID 39085080, PMID 40117530, PMID 40680855, PMID 42095986, PMID 10400410, PMID 11413430, PMID 11813623, PMID 11895791, PMID 12641522, PMID 15234753, PMID 15273542, PMID 1598671, PMID 16568451, PMID 16803844, PMID 16810012, PMID 16822992, PMID 16849762, PMID 16887481, PMID 17005947, PMID 17075117, PMID 17538089, PMID 17762433, PMID 17916545, PMID 17943760, PMID 17948223, PMID 17978289, PMID 18282805, PMID 18438113
2023 (8), 2015 (5), 2018 (5), 2017 (4), 2008 (2), 2014 (2), 2025 (2), 2016 (1), 2019 (1), K23CA115908 (1), U10CA031946 (1), U10CA037447 (1), UG1CA189823 (1)